Clinical Trial Update: A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial of adalimumab in Japanese subjects with intestinal Behçet's disease has completed and results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intestinal Behçet Disease

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Intestinal Behçet's Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-05-15